PE20010209A1 - Polimorfos de un citrato de azobiciclo[2,2,2] octan-3-amina y sus composiciones farmaceuticas - Google Patents

Polimorfos de un citrato de azobiciclo[2,2,2] octan-3-amina y sus composiciones farmaceuticas

Info

Publication number
PE20010209A1
PE20010209A1 PE2000000520A PE0005202000A PE20010209A1 PE 20010209 A1 PE20010209 A1 PE 20010209A1 PE 2000000520 A PE2000000520 A PE 2000000520A PE 0005202000 A PE0005202000 A PE 0005202000A PE 20010209 A1 PE20010209 A1 PE 20010209A1
Authority
PE
Peru
Prior art keywords
hours
octan
citrate
amine
refers
Prior art date
Application number
PE2000000520A
Other languages
English (en)
Inventor
George Joseph Quallich
Lewin Theophilus Wint
Michael James Castaldi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010209A1 publication Critical patent/PE20010209A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DEL CITRATO DE (2S,3S)-N-(METOXI-5-t-BUTILFENILMETIL-2-DIFENILMETIL-1-AZOBICICLO[2,2,2]OCTAN-3-AMINA DE FORMULA I; QUE SE CARACTERIZA PORQUE EL POLIMORFO A ESTABLE TIENE UN PATRON DE DIFRACCION DE RAYOS X, POR PRESENTARSE EN FORMA DE PLACAS; NO SER HIGROSCOPICO; SE VOLATIZA A APROXIMADAMENTE 116°C; LA TEMPERATURA DE COMIENZO DE LA FUSION ES DE 152,7°C; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE ADICIONAR ACIDO CITRICO A UNA DISOLUCION DE LA BASE LIBRE EN ACETONA, DURANTE 2 HORAS, FILTRAR Y AGITAR LA SOLUCION TRASPARENTE DURANTE LA NOCHE, ADICIONAR EL ISOPROPIL ETER FILTRADO SEGUIDO DE LA ADICION DE AGUA FILTRADA, AGITAR LA MEZCLA RESULTANTE A TEMPERATURA AMBIENTE HASTA EL COMIENZO DE LA CRISTALIZACION, GRANULAR DURANTE 16 HORAS Y RECOGER LA SAL BLANCA CRISTALINA FORMADA POR FILTRACION Y SECAR A 45°C EN VACIO CON N DURANTE 24 HORAS. EL COMPUESTO I ES UN ANTAGONISTA DE LA SUSTANCIA P Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA EMESIS
PE2000000520A 1999-06-01 2000-05-30 Polimorfos de un citrato de azobiciclo[2,2,2] octan-3-amina y sus composiciones farmaceuticas PE20010209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13699299P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
PE20010209A1 true PE20010209A1 (es) 2001-03-01

Family

ID=22475338

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000520A PE20010209A1 (es) 1999-06-01 2000-05-30 Polimorfos de un citrato de azobiciclo[2,2,2] octan-3-amina y sus composiciones farmaceuticas

Country Status (49)

Country Link
US (1) US6255320B1 (es)
EP (1) EP1181290B1 (es)
JP (1) JP3830816B2 (es)
KR (1) KR100476606B1 (es)
CN (1) CN1146565C (es)
AP (1) AP2001002349A0 (es)
AR (1) AR033331A1 (es)
AT (1) ATE244239T1 (es)
AU (1) AU767334B2 (es)
BG (1) BG65240B1 (es)
BR (1) BR0011094A (es)
CA (1) CA2372238C (es)
CO (1) CO5170463A1 (es)
CY (1) CY2007011I2 (es)
CZ (1) CZ295819B6 (es)
DE (1) DE60003679T2 (es)
DK (1) DK1181290T3 (es)
DZ (1) DZ3050A1 (es)
EA (1) EA003731B1 (es)
EC (1) ECSP003508A (es)
EE (1) EE200100656A (es)
ES (1) ES2199825T3 (es)
GT (1) GT200000087A (es)
HK (1) HK1046284A1 (es)
HN (1) HN2000000077A (es)
HR (1) HRP20010904A2 (es)
HU (1) HUP0201301A3 (es)
IL (1) IL146406A0 (es)
MA (1) MA26742A1 (es)
MX (1) MXPA01012325A (es)
MY (1) MY133508A (es)
NO (1) NO20015848L (es)
NZ (1) NZ515349A (es)
OA (1) OA11956A (es)
PA (1) PA8496101A1 (es)
PE (1) PE20010209A1 (es)
PL (1) PL196046B1 (es)
PT (1) PT1181290E (es)
SI (1) SI1181290T1 (es)
SK (1) SK285820B6 (es)
SV (1) SV2001000093A (es)
TN (1) TNSN00120A1 (es)
TR (1) TR200103473T2 (es)
TW (1) TWI285204B (es)
UA (1) UA66925C2 (es)
UY (1) UY26176A1 (es)
WO (1) WO2000073304A1 (es)
YU (1) YU81101A (es)
ZA (1) ZA200109775B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713506A1 (en) * 2004-01-30 2006-10-25 Pfizer Products Incorporated Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
RU2337685C2 (ru) * 2004-01-30 2008-11-10 Пфайзер Продактс Инк. Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза
KR100834232B1 (ko) * 2004-01-30 2008-05-30 화이자 프로덕츠 인크. 액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제
RU2320659C9 (ru) * 2004-02-02 2008-07-20 Пфайзер Продактс Инк. Способы получения 1-(2s, 3s)-2-бензгидрил-n-(5-трет-бутил-2-метоксибензил)хинуклидин-3-амина в виде камфорсульфатной соли, цитратной соли и свободного основания и промежуточное соединение
KR102391332B1 (ko) * 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
CN110577522B (zh) * 2018-06-07 2022-12-27 东莞市东阳光动物保健药品有限公司 马罗匹坦柠檬酸盐新晶型及其制备方法
CN112979639A (zh) * 2019-12-16 2021-06-18 四川科瑞德凯华制药有限公司 一种马罗皮坦新晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL171379B1 (en) * 1991-05-31 1997-04-30 Pfizer Method of obtaining novel derivatives of quinuclidine
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis

Also Published As

Publication number Publication date
JP3830816B2 (ja) 2006-10-11
GT200000087A (es) 2001-11-22
HRP20010904A2 (en) 2003-02-28
EP1181290A1 (en) 2002-02-27
UA66925C2 (uk) 2004-06-15
PT1181290E (pt) 2003-09-30
TR200103473T2 (tr) 2002-04-22
DE60003679D1 (de) 2003-08-07
KR20020010688A (ko) 2002-02-04
PL352716A1 (en) 2003-09-08
MA26742A1 (fr) 2004-12-20
CZ20014269A3 (cs) 2002-04-17
TWI285204B (en) 2007-08-11
DZ3050A1 (fr) 2004-03-27
HUP0201301A3 (en) 2002-10-28
ES2199825T3 (es) 2004-03-01
CY2007011I1 (el) 2010-07-28
SI1181290T1 (en) 2003-12-31
US6255320B1 (en) 2001-07-03
CZ295819B6 (cs) 2005-11-16
NO20015848D0 (no) 2001-11-30
UY26176A1 (es) 2000-12-29
AR033331A1 (es) 2003-12-17
DE60003679T2 (de) 2004-05-27
WO2000073304A1 (en) 2000-12-07
MY133508A (en) 2007-11-30
JP2003501354A (ja) 2003-01-14
KR100476606B1 (ko) 2005-03-18
BG65240B1 (bg) 2007-09-28
CO5170463A1 (es) 2002-06-27
NO20015848L (no) 2001-12-18
NZ515349A (en) 2004-03-26
ATE244239T1 (de) 2003-07-15
AU4424800A (en) 2000-12-18
ZA200109775B (en) 2002-11-28
HN2000000077A (es) 2001-02-02
CN1353711A (zh) 2002-06-12
CY2007011I2 (el) 2010-07-28
SK285820B6 (sk) 2007-09-06
DK1181290T3 (da) 2003-09-29
CA2372238A1 (en) 2000-12-07
CN1146565C (zh) 2004-04-21
MXPA01012325A (es) 2002-07-22
IL146406A0 (en) 2002-07-25
CA2372238C (en) 2006-12-19
TNSN00120A1 (fr) 2005-11-10
EA200101108A1 (ru) 2002-04-25
EP1181290B1 (en) 2003-07-02
BG106204A (en) 2002-07-31
AP2001002349A0 (en) 2001-12-31
ECSP003508A (es) 2002-02-25
SV2001000093A (es) 2001-11-08
HK1046284A1 (en) 2003-01-03
YU81101A (sh) 2004-07-15
HUP0201301A2 (en) 2002-08-28
EE200100656A (et) 2003-02-17
EA003731B1 (ru) 2003-08-28
PL196046B1 (pl) 2007-11-30
SK17332001A3 (sk) 2002-07-02
BR0011094A (pt) 2002-03-19
AU767334B2 (en) 2003-11-06
PA8496101A1 (es) 2002-07-30
OA11956A (en) 2006-04-13

Similar Documents

Publication Publication Date Title
ES2314593T3 (es) Forma cristalina alfa de ranelato de estroncio, su procedimiento de preparacion y composiciones farmaceuticas que la contienen.
RU2001118035A (ru) Этанолят азитромицина, процесс получения и содержащие его фармацевтические составы
PE20090124A1 (es) Composicion farmaceutica que comprende cristales de aripiprazol b de baja higroscopicidad y procedimiento de preparacion de la misma
KR970042550A (ko) Cdch의 신규 결정성 변형체, 그의 제조 방법 및 이 변형체를 함유하는 제약 제제
KR940005636A (ko) 트리아졸릴티오메틸티오 세팔로스포린 염산염, 그의 수화물 결정 및 이들의 제조방법
JPS6236381A (ja) グアニン誘導体結晶性一水和物、その製造方法及びそれを含む抗ウイルス剤
KR900001422B1 (ko) 5-클로로-3-(2-테노일)-2-옥신돌-1-카복스아미드의 무수 결정성 나트륨 염
PE20010209A1 (es) Polimorfos de un citrato de azobiciclo[2,2,2] octan-3-amina y sus composiciones farmaceuticas
SK24389A3 (en) Crystalline additive salts of 7-alpha[(2-aminothiazol-4-yl)- -alpha-(z)-methoxyiminoacetamido]-3-[(1-methyl-1- -pyrrolidino)methyl]-3-cephem-4-carboxylate, method for producing and pharmaceutical compositions comprising same
KR20070045101A (ko) 에스오메프라졸 스트론튬염 또는 이의 수화물, 이의제조방법 및 이를 포함하는 약학 조성물
PT86121B (pt) Processo para a preparacao de sal de acido 2-{(2,6-diclorofenil)-amino}-benzeno-acetico com uma base organica ciclica e de composicoes farmaceuticas contendo o mesmo
HU912768D0 (en) Process for producing codeinic salt of a substituted carboxylic acid as well as pharmaceutical preparative containing said compound
ES2226357T3 (es) Nitratos que forman parte de un medicamento antiulceroso.
RU2003134076A (ru) Клатрат гидрата азитромицина с 1,2,-пропиленгликолем, способ его получения и содержащая его фармацевтическая композиция
CY1107112T1 (el) Κρυσταλλοι τοζιλικου suplatast
ES2209110T3 (es) Nuevos derivados de acidos aninoalcano sulfonicos, fosfonicos y fosfinicos, su preparacion y su uso como medicamentos.
RU2004127981A (ru) Способ получения натриевой соли правастатина в кристаллической форме и натриевая соль правастатина, полученная этим способом
RU2008103699A (ru) Кристаллические формы динатриевой соли n-(-5-хлорсалицило-)-8-аминокаприловой кислоты
DK0480455T3 (da) Optisk aktive thienotriazolodiazepinforbindelser
FI66008C (fi) Foerfarande foer framstaellning av kristallint anhydrat av natrium-7-(d-2-hydroxi-2-fenylacetamido)-3-(1-metyl-1h-tetrazol-5-yltiometyl)-3-cefem-4-karboxylat
ATE127465T1 (de) Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen.
PT1218401E (pt) 4-benzilaminoquinolinas conjugadas com acido biliar e seus heterociclicos metodos de sua producao medicamentos contendo estes compostos e sua aplicacao
JPS5726692A (en) Preparation of stable crystal of salt of ceftizoxime
JP3574185B2 (ja) 無水クエン酸トリマグネシウムおよびその製法
US2556688A (en) Pharmaceutical methionine composition

Legal Events

Date Code Title Description
FD Application declared void or lapsed